Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

ACE-031 and LGD-4033 Interaction: Monitor | Peptide Database

Compound Profiles ACE-031 Myostatin Inhibitor | Experimental Muscle Growth ACE-031 acts as a ligand trap for members of the TGF-beta superfamily. By mimicking the extracellular domain of the ActRIIB receptor, it intercepts myostatin (GDF-8), activin A, activin

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

ACE-031

Myostatin Inhibitor | Experimental Muscle Growth

ACE-031 acts as a ligand trap for members of the TGF-beta superfamily. By mimicking the extracellular domain of the ActRIIB receptor, it intercepts myostatin (GDF-8), activin A, activin B, and GDF-11 before they can bind cell-surface receptors and activate Smad2/3 signaling.

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take ACE-031 with LGD-4033?

Yes, but with caution. Both ACE-031 and LGD-4033 suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. Regular monitoring is advised.

Is ACE-031 and LGD-4033 safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: androgenic, blood pressure raising, hpta suppressive, lipid disrupting, teratogenic. Monitor accordingly.

What are the interactions between ACE-031 and LGD-4033?

Both ACE-031 and LGD-4033 suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. This assessment has 46% confidence and is inferred from pharmacological mechanism analysis.

How should I time ACE-031 and LGD-4033?

ACE-031 has a half-life of 12-15 days and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

ACE-031 vs Myostatin Antibodies

Myostatin-specific antibodies represent another mechanistic approach to myostatin inhibition. Unlike ACE-031’s soluble receptor strategy: Antibodies: Directly bind myostatin protein itself …

Source: peptideslabuk.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Phase 1 data showed statistically significant lean mass increases (average +1.7%) after a single IV dose in healthy postmenopausal women. Phase 2 trial in DMD patients showed improvements in lean body mass and bone mineral density, but trial was halted due to vascular adverse events. Preclinical models demonstrate robust prevention of muscle loss in disease states through myostatin pathway inhibition. Phase 1 trial subjects showed concurrent fat mass reductions alongside lean mass gains, suggesting favorable nutrient partitioning. DMD trial data showed increases in bone mineral density, consistent with known effects of ActRIIB pathway modulation on bone metabolism.

Source: peptide-db.com ↗

Research Value Beyond DMD

The ACE-031 experience substantially advanced understanding of the ActRIIB ligand family’s biology in humans. From a research perspective: The demonstrated rapid lean mass accrual in DMD patients confirmed that myostatin/activin inhibition is an effective anabolic strategy in diseased human muscle — a key proof of principle for the entire myostatin inhibitor class. The vascular adverse effects mapped the biology of activin A in human vascular endothelium — findings that have informed the development of next-generation inhibitors with improved safety profiles by sparing activin A signalling. ACE-031’s pharmacology has been studied in bone biology (ActRIIB signalling also regulates bone density, and soluble ActRIIB-Fc increases bone mineral density in preclinical models) and reproductive biology (activin and GDF-11 have roles in FSH regulation and reproductive axis modulation). For researchers studying the broader TGF-β superfamily biology, ACE-031 is a valuable tool precisely because of its broad ligand capture profile.

Source: peptideslabuk.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

ACE-031 (1 mg) Dosage Protocol

A soluble activin receptor type IIB (ActRIIB) Fc-fusion protein that traps myostatin and related muscle-limiting factors. Its clinical development was halted for safety. Research-use-only — this page is an educational reference and a caution, not a dosing recommendation.

Source: dosagepeptide.com ↗
Storage reference

Usage and Storage:

ACE-031 is supplied as a lyophilised solid to ensure maximum stability and ease of use in research environments. For best results, follow our website's detailed reconstitution and storage guidelines.

Source: uk-peptides.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides